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Abstract  
Horses, like humans, can experience bone fractures and due to their large size and need to 
bear weight on all limbs during the recovery period, they can be difficult to treat. Surgical 
techniques to improve fracture repair are improving, but to date, regenerative medicine 
technologies to aid fracture healing are not commonly applied in horses. 
 We have previously demonstrated that equine induced pluripotent stem cells 
(iPSCs) can be differentiated into bone forming osteoblasts in 2D culture. Here we report 
on the use of a thermoplastic, 3D printed polymer to provide a scaffold for successful, in 
vitro osteoblast differentiation of equine iPSCs. The scaffold provides a transparent, cost 
effect solution to allow the analysis of osteoblast differentiation using live cell imaging, 
immunohistochemistry and quantitative PCR. This in vitro study demonstrates the future 
feasibility of generating 3D bone constructs through the cell seeding of scaffolds to use in 
regenerative medicine strategies to improve fracture repair in a relevant, large animal 
model. 
Impact statement 
Here we describe the use of a cost-effective scaffold that can be used for in vitro studies of 
osteoblast differentiation by stem cells. The scaffolds can be printed to any size and shape, 
conditioned to improve cell adherence and they are transparent to allow clear 
visualisation of the cells in culture or post immunohistochemical staining. Osteoblast 
differentiation of equine iPSCs was successfully performed and analysed on a 3D printed 
scaffold, which allows the future development of bone constructs to aid fracture repair in 
horses.  
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Introduction 
Fractures caused by bone overloading or direct trauma are a significant welfare issue in 
multiple horse breeds taking part in a range of different disciplines1. Severe fracture leads 
to euthanasia, whereas smaller fractures can be treated conservatively with box rest and a 
cast. In delayed union or comminuted fractures surgery is required2 but up to 40% of 
horses do not return to their previous athletic activity3. Regenerative medicine strategies 
using bone tissue engineering to improve fracture reunion and recovery would significantly 
improve horse welfare.  
Bone grafts are used to promote bone regeneration and restore normal bone 
architecture in humans4, however it is difficult to obtain sufficient tissue without donor 
site morbidity. In horses, autologous bone grafting has been performed for many years5,6, 
but the effects on the donor site can be even more catastrophic, as the loss of tissue can 
lead to fracture at the donor site as the horse recovers from anaesthesia7. Using stem cells 
to enhance tissue healing is therefore becoming a popular alternative in both species8-10.  
Induced pluripotent stem cells are cells that are derived from somatic adult cells 
and have been reprogrammed such that they resemble an embryonic-like state and are 
capable of indefinite proliferation and can form cells from all three germ line lineages 
(endoderm, ectoderm and mesoderm)11 including bone-forming osteoblasts12-14. We have 
successfully generated iPSC lines from equines15 and have developed methods to 
differentiate the iPSCs into osteoblasts using traditional 2D cell culture techniques16. 
Equine iPSCs may therefore have the potential to provide large numbers of osteoblasts to 
utilise in tissue engineering strategies to aid fracture repair in horses. 
It has been well documented that compared to 2D cultures, 3D systems provide 
more accurate modelling of the physiological and cellular environment of cells and 
promote and maintain lineage specific differentiation and normal cellular architecture17-19. 
The use of iPSCs with 3D scaffolds to enhance cell attachment, proliferation and matrix 
deposition offer a promising option in regenerative medicine and allow cell organisation 
that is more closely related to native tissues than 2D culture20. However, to date there are 
no reports differentiation of equine iPSCs into osteoblasts on a 3D scaffold.  
The overall aim of this study was to assess the potential of a 3D-printed polymer 
scaffold to support in vitro osteoblastic differentiation of equine iPSCs. . 
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Materials and Methods 
Thermoplastic 3D printed polymers 
Thermoplastic polymers Polycarbonate BendLay 3D Filament, transparent finish (Orbi-
Tech) were printed using a Fused Deposition Modelling 3D printer (MakerBot Replicator 2 
Desktop 3D Printer). The following printer settings were used: slicing setting was 0.2 mm, 
travel speed of the extrusion nozzle was 150 mm/s, z-axis speed was 23 mm/s, extruder 
temperature was 215°C, feeding rate of the filament was 30 mm/s, infill density was 100%, 
nozzle diameter was 0.4 mm and the filament diameter was 1.77 mm. The pore size was 
set at 400 µm. The total thickness of the scaffolds was 1.66 mm, with each scaffold layer 
being 0.2 mm thick. Three different scaffold diameters were tested: 15.14 mm, 14.90 mm 
and 14.60 mm. Two scaffold types were tested; open scaffolds and closed scaffolds. The 
only difference between them being the presence of a fine mesh (150 µm pore size) on the 
base of the closed scaffolds. Where present, a single layer of the fine mesh (0.2 mm thick) 
was printed as a continuation of the main scaffold.  
The scaffold surface was conditioned by oxygen etching using a Bio Rad PT7125 
Barrel Plasma Etcher at 150 W, under 2 millibars pressure for 2 hrs to enhance cell 
adhesion. After printing, the scaffolds were preserved in a sealed container indefinitely at 
room temperature. After the oxygen etching, the scaffolds were preserved in a sealed 
container and stored at -20°C degrees until further use, or at 4°C for up to 6 weeks. 
Scanning Electron Microscope (SEM) 
The scaffolds seeded with 3T3 cells and cultured were fixed with 4% paraformaldehyde 
solutions in PBS overnight prior to gold coating on the sputter machine. The scaffold 
samples were loaded on to aluminium stubs with carbon tabs pre-fixed. The samples were 
gold coated using a Polaron SC7640 sputter coater, manufactured by Quorum 
Technologies.  The coating parameters were 2.2 kV, 20 mA, 55 mm form Au target, 30 sec 
coating. The coated samples were washed three times with PBS and left to air dry prior to 
imaging on the Scanning Electron Microscope machine for imaging, (JSM 5900LV 
manufactured by JEOL fitted with a tungsten filament, acceleration voltage was set at 20 
kV, and working distance was 12 mm).  
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Cell culture 
Mouse 3T3 fibroblasts (from ATTC, Middlesex, UK) were cultured in DMEM supplemented 
with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin (all from Invitrogen, Renfrewshire, UK). They were passaged upon reaching 
80% confluency using trypsin-EDTA (Sigma-Aldrich, Dorset, UK) at a ratio of 1:3 and 
cultured on the scaffolds for 9 days prior to SEM. 
Human osteosarcoma cell line Saos-2 cells (HTB-85 from ATTC) were cultured in 5% 
CO2, 37
oC in McCoys 5A medium with 15% fetal bovine serum, 2 mM L-glutamine, 100 
U/ml penicillin, 100 µg/ml streptomycin (all from Invitrogen). They were passaged when 
confluent using trypsin-EDTA at a ratio of 1:3. They were modified to constitutively express 
GFP using retroviral integration. Briefly, phoenix-gag-pol (PGP) cells were transfected with 
3 µg of pMX.GFP (Cell Biolabs, San Diego, CA, USA) and 3 µg of pVPack-VSV-G envelope 
protein (Strategene) using lipofectamine 2000 and Optimem media (both Invitrogen) 
according to the manufacturer’s instructions. After 48 hrs viral supernatant was sterile 
filtered through a 0.45 µM filter (Nalgene) and added to Saos-2 cells. Three rounds of viral 
infection were carried out at 48 hour intervals which resulted in over 90% of Saos-2 cells 
expressing GFP. 
 Six lines of previously derived equine iPSCs15,16 from three different horses were 
cultured on mitotically inactivated mouse embryonic fibroblasts in DMEM/F12, 
supplemented with: 15% FCS, 2 mM L-glutamine, 1% non-essential amino acids, 1 mM 
sodium pyruvate, 0.1 mM 2-mercaptoethanol (all Invitrogen), 1000 U/ml leukaemia 
inhibitory factor (LIF, Sigma), and 10 ng/ml basic fibroblast growth factor (bFGF, 
Peprotech, NJ, USA). Colonies were passaged mechanically every 5 to 7 days in the 
presence of 2 μM Thiazovivin (StemGent, Cambridge, MA).  
Bone differentiation on the constructs was carried out in osteoblast differentiation 
media. This consisted of the iPSC base medium (lacking bFGF and LIF) or the Saos-2 base 
medium supplemented with 10 mM β-glycerophosphate, 50 µM ascorbic acid and 1 µM 
dexamethasone (all Sigma-Aldrich).  
 Prior to cell seeding the constructs were sterilised under UV light (10 minutes per 
side) and conditioned with the cell-type appropriate media overnight. 1x 104 cells were 
seeded onto each construct for all cell types. 3T3 and Saos-2 cells were seeded as single 
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cells and iPSCs were seeded as small colonies following mechanical passaging. 
Differentiation was carried out for 21 days with media replaced every 2-3 days. 
Bone differentiation assays 
To determine matrix mineralisation entire constructs were stained with von Kossa (Abcam, 
Cambridgeshire, UK) according to the manufacturer’s instructions. Alizarin Red S staining 
for calcium deposition was performed by incubating the entire constructs with 2% Alizarin 
Red S pH 4.2 for 5 min. Hydroxyapatite deposition was detected using the OsteoImage 
bone mineralisation assay (Lonza, Berkshire, UK) according to the manufacturer’s 
instructions. Alkaline phosphatase activity was measured using a quantitative colorimetric 
test on cell culture supernatant (Abcam) according to the manufacturer’s instructions. 
Activity is measured in glycine units/ml where one glycine unit is the amount of enzyme 
causing the hydrolysis of one micromole of pNPP (p-nitrophenyl phosphate) per minute at 
pH 9.6 and 25°C. 
RNA extraction, cDNA synthesis and qRT-PCR 
RNA was extracted using Tri-reagent (Sigma-Aldrich), purified using the RNeasy mini kit 
(Qiagen, Manchester, UK) and treated with Ambion DNA-free (Life Technologies, Paisley, 
UK). cDNA was made from 1 μg of RNA using the sensiFAST cDNA synthesis kit (Bioline, 
London, UK). 2 μl aliquots of cDNA were used in qPCR. Primers were designed using NCBI 
Primer-Blast (https://www.ncbi.nlm.nih.gov/tools/primer-blast/). Primer sequences can be 
found in Table 1. qPCR was carried out using SYBR Green containing supermix (Bioline) on 
the Biorad C1000 Touch Thermal Cycler (Biorad, Hertfordshire, UK), and all  PCR reactions 
performed in duplicate. PCR cycle parameters were 95°C for 10 min, followed by 40 cycles 
of 95°C for 15 seconds, 60°C for 15 seconds and 72°C for 15 seconds. At the end of the 
program a melt curve was produced by taking readings every 1°C from 65°C to 95°C. 18s 
rRNA levels did not change between treatments (data not shown) and was used to 
normalise gene expression using the 2-ΔΔCt method 21. 
Immunohistochemistry 
This was performed on the entire constructs. The cells on the constructs were fixed in 3% 
paraformaldehyde for 20 min and permeabilised for 1h with 0.1% triton-X-100. They were 
washed in PBS and incubated with the primary antibodies overnight at 4°C before 
detection with an appropriate fluorescently labelled secondary antibody. All antibodies 
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were used at optimized concentrations in PBS and appropriate negative controls were 
performed using secondary antibodies alone and IgG matched to the host species, as well 
as specific isotype of the primary antibody. Coverslips were mounted using Vectashield 
Hardset mounting medium containing DAPI (4',6-diamidino-2-phenylindole, Vector 
Laboratories, Cambridge, UK). Primary antibodies included: mouse anti-collagen type I 
1:100 (AB90395 Abcam, Cambridge, UK), mouse anti-osteonectin (SPARC) 1:20 (MAB941-
100, Biotechne, Oxford, UK), mouse anti-osteopontin (SPP1) 1:50 (21742, Santa Cruz 
biotechnology, CA, USA), rabbit anti-bone sialoprotein (IBSP) 1:100 (ORB1100, Biorbyt, 
Cambridge, UK), rabbit anti-RUNX2 1:50 (10758, Santa Cruz), goat anti-osteocalcin (BGALP) 
1:50 (18319, Santa Cruz). Secondary antibodies were goat anti-mouse alexafluor 594 1:200 
(A11005, Invitrogen), goat anti-rabbit alexafluor 594 1:200 (A11012, Invitrogen) and rabbit 
anti-goat alexafluor 594 1:200 (Ab150144, Abcam). Constructs were inverted for imaging 
on a fluorescent microscope. 
Results 
Scaffold optimisation 
To fit into a standard 24 well tissue culture plate, the optimal size which allowed the 
insertion and removal of constructs from the well while minimising the growth of cells 
under and around the construct was found to be 14.90 mm height, 14.90 mm width, 
thickness 1.66 mm (Figure 1). 
The surface coating was optimised to ensure the maximum adherence and growth 
of cells on the surface. Scanning EM revealed the adherence of 3T3 cells within the 
meshwork of the scaffold (Figure 2A). 
  Two types of construct were tested; open constructs and closed constructs. The 
closed constructs had a fine mesh layer that coated the bottom of the construct, enclosing 
it as a more isolated unit for cell growth, whereas the open construct lacked this fine mesh 
layer, meaning cells were free to penetrate through the construct and adhere to the 
bottom of the cell culture plate (Figure 2B). Saos-2 cells expressing GFP were able to 
adhere to the scaffold of both construct types, but the open constructs with no mesh had 
far fewer cells remaining within the construct and many cells present on the bottom of the 
culture dish. In contrast the enclosed construct did not allow any cells to pass through to 
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the bottom of the culture dish. Enclosed constructs were therefore used in all further 
experiments.  
iPSCs and Soas-2 cells differentiated on the 3D scaffold produce a mineralised matrix 
GFP-labelled equine iPSCs were seeded as small colonies onto the constructs. These 
adhered to the constructs and individual cells migrated away from the colonies along the 
scaffold but after 21 days of differentiation the iPSC-derived cells were fewer in number 
and less evenly distributed than Saos-2 cells (Figure 3). Despite the ability of the cells to 
move through the pores, cells were attached throughout the depth of the scaffold (rather 
than just on the base of the enclosed construct). This can be seen in Figure 3 where the 
cells are clearly present on the scaffold layers containing pores of 450 µm. 
 Alizarin red S and von Kossa staining on the entire constructs demonstrated that 
calcium had been deposited by both Saos-2 and iPSCs following 21 days of culture in 
osteoblast differentiation medium (Figure 4 A and B). More intense and global staining of 
constructs seeded with Saos-2 cells was observed than in constructs seeded with iPSCs. 
Control constructs in which no cells had been seeded did not produce any positive 
staining. 
 Non-GFP labelled iPSCs were seeded onto constructs in osteoblast differentiation 
media for 21 days prior to fluorescent detection of hydroxyapatite. Clear deposition of 
hydroxyapatite could be visualised on the scaffold (Figure 4C). All Saos-2 cells used in these 
3D studies were labelled with GFP and therefore we were not able perform fluorescent 
detection of hydroxyapatite on the Saos-2 seeded scaffolds. 
iPSCs and Soas-2 cells differentiated on the 3D scaffold synthesise alkaline phosphatase  
A low level of ALP activity was produced by undifferentiated iPSCs but the level of ALP 
activity increased over the 21 days of differentiation by 20.5 fold (Figure 5). This was still 
lower than the level of ALP activity for the Saos-2 cells which was 1.5 fold higher than for 
the iPSCs after 21 days of differentiation. 
iPSCs differentiated on the 3D scaffold express osteoblast-associated genes and proteins 
After 21 days of differentiation on the 3D scaffolds the iPSCs expressed the osteoblast 
associated genes COL1A1 (collagen type I), SPARC (osteonectin), RUNX2 (Runt Related 
Transcription Factor 2), SPP1 (osteopontin) and BGLAP (osteocalcin), but no expression of 
IBSP (Integrin Binding Sialoprotein) was detected (Figure 6). Similarly, 
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immunohistochemical staining for osteoblast-associated proteins revealed positive, cell-
associated staining for COL1A1, SPARC, RUNX2, SPP1 and BGALP but not IBSP (Figure 6). 
Gene and protein expression for the Saos-2 was not examined in this study. 
Discussion 
We have previously reported the successful 2D differentiation of equine iPSCs into 
osteoblasts16 and here we report the use of a novel, thermoplastic 3D printed scaffold to 
allow in vitro 3D osteoblast differentiation of equine iPSCs. 
 The filament used to make the scaffolds is biocompatible22, cheap to purchase and 
can be printed to any size or shape. Importantly, it is also optically transparent, whereas 
other printable polymers such as polylactide (PLA) and polycaprolactone (PCL) are opaque. 
. Here we optimised the scaffold fit to a standard 24 well tissue culture plate and 
performed oxygen etching to allow good adhesion of the cell types being tested. Without 
surface treatment cells do not attach to the Bendlay polymer. The polymer can be coated 
with other proteins such as fibronectin, collagen type I and laminin to promote cell 
adhesion (unpublished data), but we have only determined equine iPSC attachment and 
differentiation on oxygen etched polymers. This is a similar process to that performed in 
the manufacture of tissue culture plastics.  We found that enclosed constructs containing a 
fine mesh layer on the base, retained the cells within the scaffold much more effectively 
than open scaffolds lacking the mesh layer, where many cells were found adhered to the 
bottom of the cell culture well. We did not test the use of ultra-low attachment culture 
plates in this work, but if open scaffolds are required (for example to improve blood vessel 
infiltration in vivo) low attachment plates may help encourage cell retention on the 
scaffolds rather than on the culture plate itself. Pores within the scaffold allow the 
diffusion of nutrients and cellular proliferation, migration and communication. A wide 
range of pore sizes have been used in bone tissue engineering, ranging from 20 µm to 
1500 µm23 and here we demonstrated that a combination of 150 µm and 400 µm provided 
an effective scaffold for in vitro differentiation and analysis. 
 Here we used scaffolds which were 1.66 mm thick and found that we had very 
good distribution of the cells throughout the depth of the scaffold. However, future work 
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to determine the effect of scaffold thickness on cell survival, migration and differentiation 
is required as the diffusion of nutrients may become limited as the thickness increases. 
The transparency of the scaffold is of great benefit for in vitro studies as it allows 
the distribution and growth of the cells to be visualised during standard culture. How cells 
are distributed, proliferate and differentiate on a scaffold can all effect the likely 
functionality of the engineered tissue24 and assessing this on non-transparent scaffolds 
requires additional techniques to be performed25. Furthermore, transparent scaffolds 
enable the use of the same protocols for the end point analysis of differentiation to be 
conducted as for 2D differentiation (e.g. immunocytochemical staining). Therefore, as a 
tool for studying in vitro bone differentiation this scaffold provides a cost-effective option 
that allows robust post-differentiation analyses to be performed. 
Saos-2 cells seeded onto the constructs as single cells exhibited a very even 
distribution throughout the scaffold after 21 days of culture, whereas equine iPSCs, seeded 
as small colonies, were less well distributed after 21 days of culture and future work to 
enable the seeding of the iPSCs as single cells would likely be beneficial. Nevertheless, 
iPSCs did grow out of the original colonies along the meshwork of the scaffold. However, 
we were unable to find a successful method for extracting live cells from the scaffold to 
determine actual cell numbers at the end of the 21 days of differentiation. The extraction 
of live cells is likely complicated by the fact that upon differentiation into osteoblasts the 
cells produce a mineralised matrix16. 
 We used both Alizarin red S and von Kossa staining to detect calcium production by 
the differentiated iPSCs and acknowledge that von Kossa reacts with the anionic portion of 
many salts and is not specific for calcium26. The iPSC-seeded constructs demonstrated 
distinct patches of calcium deposition, which may correlate with areas containing more 
cells, indicating successful osteoblast differentiation. Saos-2 seeded constructs were used 
as a positive control and had much more observable Alizarin red S and von Kossa staining 
which was evenly distributed across the constructs. This likely reflects the even 
distribution of the Saos-2 cells and the fact that as a human osteosarcoma cell line they 
readily undergo osteoblast differentiation to produce a mineralised matrix27. Non-GFP 
labelled equine iPSCs were also seeded on constructs and used to detect hydroxyapatite. 
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Clear deposition of hydroxyapatite was visible on the meshwork of the scaffold supporting 
conclusion that the iPSCs had differentiated into osteoblasts. 
 Bone mineralised requires the activity of alkaline phosphatase (ALP)28 and we 
demonstrated that over the 21 days of differentiation there is an increase ALP activity. As 
we reported previously16, and similar to human and mouse ESCs29, undifferentiated equine 
iPSCs express a low level of ALP. ALP activity is increased approximately 20.5 fold after 21 
days of differentiation in 3D. In comparison, we previously reported that ALP activity is 
only increased approximately 6 fold after 21 days of 2D differentiation16, but we have not 
performed these experiments in parallel. ALP activity was only measured in one replicate 
of Saos-2 differentiation and so it was not possible to perform a statistical analysis, 
however, the level of ALP activity was higher in differentiating Saos-2 cells than iPSCs. 
 Quantitative PCR and immunohistochemistry produced matching results and 
demonstrated the expression of COL1A1, SPARC, SPP1, RUNX2 and BGALP by the 
differentiated equine iPSCs at both the gene and the protein level. Of note, the iPSCs that 
had grown out of the original colonies and existed as single cells on the scaffold were 
positive for the bone protein markers. This demonstrates that the migrating cells do 
undergo differentiation. However, no gene or protein expression was detected for IBSP. 
We have previously demonstrated that IBSP expression following 2D differentiation of 
equine iPSCs shows large amounts of inter-horse variability16. However, it may also reflect 
the fact that IBSP (bone sialoprotein) is a later marker of osteoblastic differentiation than 
the others that were tested30,31. RUNX2 is a key transcription factor in the osteoblast 
differentiation pathway32,33 and has a relatively high expression after 21 days of iPSC 
differentiation. Similarly, COL1A1 and SPARC have relatively high gene expression levels. 
These are upregulated in the early phases of differentiation34,35 and are considered to be 
early markers of osteoblast differentiation36-38. In contrast, BGALP and SPP1 have lower 
expression levels and are both required in the later stages of bone formation36,39,40. 
Although these analyses were only performed on a single line of iPSCs and further 
replicates are required, they do suggest that the iPSCs may require additional time in 
culture to generate a more mature osteoblast phenotype. Alternatively, as the material 
used in the scaffold has been shown to affect the efficiency of bone differentiation of a 
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variety of cell types17,41,42, coating the scaffold with osteogenic factors may lead to more 
efficient differentiation of the iPSCs. 
 Improving the efficiency of differentiation of iPSCs is particularly important with 
regard to their clinical application because any remaining undifferentiated cells may have 
the potential to undergo uncontrolled proliferation and tumour formation in vivo43. As we 
were not able to extract live cells from the scaffold, it was not possible to quantify the 
efficiency of differentiation of the iPSCs, for example using flow cytometry. Other methods 
using an intermediate differentiation step to mesenchymal stem cells (MSCs)44 and 
removal of any undifferentiated iPSCs (using cell sorting) prior to 3D differentiation may 
help to reduce the safety concerns of using iPSC derived products clinically. Future work to 
determine the optimal duration of 3D differentiation is also required as in this study we 
only examined differentiation after 21 days.  
 These polycarbonate scaffolds are not biodegradable and would not break down 
over time in vivo in line with tissue healing. However, many non-biodegradable 
scaffolds/implants are used in in vivo fracture repair such as metals and PAA (polyacrylic 
acid)45 and generally biodegradable scaffolds have poorer mechanical properties that can 
make them unsuitable for fracture repair in bones exposed to large forces45,46. The 
polycarbonate scaffolds used in this report can be easily scaled up and printed to any size 
or shape and can be fabricated rapidly. This would allow them to be custom produced to 
fit individual bone defects, whilst ensuring that the material, pore size etc remains 
standardised. Polycarbonate is lightweight but has a high tensile strength of 77 MPa and a 
high tensile break strength of 75-150% which means that it can withstand high loads and 
torsional stress far better than other thermoplastics which have been used in bone repair 
such as PLA (polylactide)47 and PMMA (polymethyl methacrylate)48. This is of particular 
importance for equine clinical applications where limb bones are exposed to high loads 
and the native tissue has a high ultimate tensile strength of around 120 MPa49. 
 In summary we report that equine iPSCs can be successfully differentiated into 
bone forming osteoblasts on a thermoplastic, 3D printed polymer which form the 
development of novel methods for improving fracture repair in horses in the future. 
 
 
D
ow
nl
oa
de
d 
by
 T
H
E 
U
N
IV
ER
SI
TY
 O
F 
M
A
N
CH
ES
TE
R 
fro
m
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
3/
08
/1
9.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 13 of 26 
 
 
 
13 
Ti
ss
u
e 
En
gi
n
ee
ri
n
g 
B
io
co
m
p
at
ib
le
 3
D
 p
ri
n
te
d
 t
h
er
m
o
p
la
st
ic
 s
ca
ff
o
ld
s 
fo
r 
o
st
eo
b
la
st
 d
if
fe
re
n
ti
at
io
n
 o
f 
eq
u
in
e 
iP
S 
ce
lls
 (
D
O
I:
 1
0
.1
0
8
9
/t
en
.T
EC
.2
0
1
8
.0
3
4
3
) 
Th
is
 p
ap
er
 h
as
 b
e
e
n
 p
ee
r-
re
vi
e
w
ed
 a
n
d
 a
cc
ep
te
d
 f
o
r 
p
u
b
lic
at
io
n
, b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
go
 c
o
p
ye
d
it
in
g 
an
d
 p
ro
o
f 
co
rr
e
ct
io
n
. T
h
e 
fi
n
al
 p
u
b
lis
h
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
 
Acknowledgements 
The authors would like to thank The PetPlan Charitable Trust for funding this work (Project 
number: 227-265). 
Author Disclosure Statement 
No competing financial interests exist. 
  
D
ow
nl
oa
de
d 
by
 T
H
E 
U
N
IV
ER
SI
TY
 O
F 
M
A
N
CH
ES
TE
R 
fro
m
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
3/
08
/1
9.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 14 of 26 
 
 
 
14 
Ti
ss
u
e 
En
gi
n
ee
ri
n
g 
B
io
co
m
p
at
ib
le
 3
D
 p
ri
n
te
d
 t
h
er
m
o
p
la
st
ic
 s
ca
ff
o
ld
s 
fo
r 
o
st
eo
b
la
st
 d
if
fe
re
n
ti
at
io
n
 o
f 
eq
u
in
e 
iP
S 
ce
lls
 (
D
O
I:
 1
0
.1
0
8
9
/t
en
.T
EC
.2
0
1
8
.0
3
4
3
) 
Th
is
 p
ap
er
 h
as
 b
e
e
n
 p
ee
r-
re
vi
e
w
ed
 a
n
d
 a
cc
ep
te
d
 f
o
r 
p
u
b
lic
at
io
n
, b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
go
 c
o
p
ye
d
it
in
g 
an
d
 p
ro
o
f 
co
rr
e
ct
io
n
. T
h
e 
fi
n
al
 p
u
b
li
sh
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
 
References 
1 Morgan, R. & Dyson, S. Incomplete longitudinal fractures and fatigue injury of the 
proximopalmar medial aspect of the third metacarpal bone in 55 horses. Equine Vet 
J 44, 64-70, doi:10.1111/j.2042-3306.2011.00371.x (2011). 
2 Cahn, C. M. The Merck Veterinary Manual.  (John Wiley & Sons, 2010). 
3 Payne, R. J. & Compston, P. C. Short- and long-term results following standing 
fracture repair in 34 horses. Equine Vet J 44, 721-725, doi:10.1111/j.2042-
3306.2012.00569.x (2012). 
4 Ma, J. et al. Concise review: cell-based strategies in bone tissue engineering and 
regenerative medicine. Stem cells translational medicine 3, 98-107, 
doi:10.5966/sctm.2013-0126 (2014). 
5 Boero, M. J. et al. Evaluation of the tibia as a source of autogenous cancellous bone 
in the horse. Veterinary surgery : VS 18, 322-327 (1989). 
6 RICHARDSON, G. L., POOL, R. R., PASCOE, J. R. & WHEAT, J. D. Autogenous 
Cancellous Bone Grafts From the Sternum in Horses Comparison With Other Donor 
Sites and Results of Use in Orthopedic Surgery. Veterinary Surgery 15, 9-15, 
doi:doi:10.1111/j.1532-950X.1986.tb00166.x (1986). 
7 Harriss, F. K., Galuppo, L. D., Decock, H. E., McDuffee, L. A. & Macdonald, M. H. 
Evaluation of a technique for collection of cancellous bone graft from the proximal 
humerus in horses. Veterinary surgery : VS 33, 293-300, doi:10.1111/j.1532-
950x.2004.04043.x (2004). 
8 Jones, E. A., Giannoudis, P. V. & Kouroupis, D. Bone repair with skeletal stem cells: 
rationale, progress to date and clinical application. Therapeutic advances in 
musculoskeletal disease 8, 57-71, doi:10.1177/1759720X16642372 (2016). 
9 Perez, J. R. et al. Tissue Engineering and Cell-Based Therapies for Fractures and 
Bone Defects. Frontiers in bioengineering and biotechnology 6, 105-105, 
doi:10.3389/fbioe.2018.00105 (2018). 
10 McDuffee, L. A. et al. Osteoprogenitor cell therapy in an equine fracture model. 
Veterinary surgery : VS 41, 773-783, doi:10.1111/j.1532-950X.2012.01024.x (2012). 
 
 
D
ow
nl
oa
de
d 
by
 T
H
E 
U
N
IV
ER
SI
TY
 O
F 
M
A
N
CH
ES
TE
R 
fro
m
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
3/
08
/1
9.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 15 of 26 
 
 
 
15 
Ti
ss
u
e 
En
gi
n
ee
ri
n
g 
B
io
co
m
p
at
ib
le
 3
D
 p
ri
n
te
d
 t
h
er
m
o
p
la
st
ic
 s
ca
ff
o
ld
s 
fo
r 
o
st
eo
b
la
st
 d
if
fe
re
n
ti
at
io
n
 o
f 
eq
u
in
e 
iP
S 
ce
lls
 (
D
O
I:
 1
0
.1
0
8
9
/t
en
.T
EC
.2
0
1
8
.0
3
4
3
) 
Th
is
 p
ap
er
 h
as
 b
e
e
n
 p
ee
r-
re
vi
e
w
ed
 a
n
d
 a
cc
ep
te
d
 f
o
r 
p
u
b
lic
at
io
n
, b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
go
 c
o
p
ye
d
it
in
g 
an
d
 p
ro
o
f 
co
rr
e
ct
io
n
. T
h
e 
fi
n
al
 p
u
b
lis
h
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
 
11 Baird, A. E., Barsby, T. & Guest, D. J. Derivation of Canine Induced Pluripotent Stem 
Cells. Reprod Domest Anim 50, 669-676. doi: 610.1111/rda.12562. Epub 12015 Jun 
12512. (2015). 
12 Kang, H., Shih, Y. V. & Varghese, S. Direct Conversion of Human Pluripotent Stem 
Cells to Osteoblasts With a Small Molecule. Curr Protoc Stem Cell Biol 44, 1f.21.21-
21f.21.26, doi:10.1002/cpsc.44 (2018). 
13 Kang, H., Shih, Y. R., Nakasaki, M., Kabra, H. & Varghese, S. Small molecule-driven 
direct conversion of human pluripotent stem cells into functional osteoblasts. 
Science advances 2, e1600691, doi:10.1126/sciadv.1600691 (2016). 
14 Wu, Q. et al. Deriving Osteogenic Cells from Induced Pluripotent Stem Cells for 
Bone Tissue Engineering. Tissue engineering. Part B, Reviews 23, 1-8, 
doi:10.1089/ten.TEB.2015.0559 (2017). 
15 Bavin, E. P., Smith, O., Baird, A. E. G., Smith, L. C. & Guest, D. J. Equine induced 
pluripotent stem cells have a reduced tendon differentiation capacity compared to 
embryonic stem cells. Frontiers in Veterinary Science 2, 
doi:10.3389/fvets.2015.00055 (2015). 
16 Baird, A. et al. Osteoblast differentiation of equine induced pluripotent stem cells. 
Biology Open, doi:10.1242/bio.033514 (2018). 
17 Polo-Corrales, L., Latorre-Esteves, M. & Ramirez-Vick, J. E. Scaffold design for bone 
regeneration. Journal of nanoscience and nanotechnology 14, 15-56 (2014). 
18 Shekaran, A. et al. Enhanced in vitro osteogenic differentiation of human fetal MSCs 
attached to 3D microcarriers versus harvested from 2D monolayers. BMC 
Biotechnol 15, 102, doi:10.1186/s12896-015-0219-8 (2015). 
19 Ravi, M., Paramesh, V., Kaviya, S. R., Anuradha, E. & Solomon, F. D. 3D cell culture 
systems: advantages and applications. J Cell Physiol 230, 16-26, 
doi:10.1002/jcp.24683 (2015). 
20 de Peppo, G. M. et al. Engineering bone tissue substitutes from human induced 
pluripotent stem cells. Proceedings of the National Academy of Sciences of the 
United States of America 110, 8680-8685, doi:10.1073/pnas.1301190110 (2013). 
21 Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real 
time quantitative PCR and the 2-deltadeltaCT Method. Methods 25, 402-408 (2001). 
D
ow
nl
oa
de
d 
by
 T
H
E 
U
N
IV
ER
SI
TY
 O
F 
M
A
N
CH
ES
TE
R 
fro
m
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
3/
08
/1
9.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 16 of 26 
 
 
 
16 
Ti
ss
u
e 
En
gi
n
ee
ri
n
g 
B
io
co
m
p
at
ib
le
 3
D
 p
ri
n
te
d
 t
h
er
m
o
p
la
st
ic
 s
ca
ff
o
ld
s 
fo
r 
o
st
eo
b
la
st
 d
if
fe
re
n
ti
at
io
n
 o
f 
eq
u
in
e 
iP
S 
ce
lls
 (
D
O
I:
 1
0
.1
0
8
9
/t
en
.T
EC
.2
0
1
8
.0
3
4
3
) 
Th
is
 p
ap
er
 h
as
 b
e
e
n
 p
ee
r-
re
vi
e
w
ed
 a
n
d
 a
cc
ep
te
d
 f
o
r 
p
u
b
lic
at
io
n
, b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
go
 c
o
p
ye
d
it
in
g 
an
d
 p
ro
o
f 
co
rr
e
ct
io
n
. T
h
e 
fi
n
al
 p
u
b
li
sh
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
 
22 Salentijn, G. I., Oomen, P. E., Grajewski, M. & Verpoorte, E. Fused Deposition 
Modeling 3D Printing for (Bio)analytical Device Fabrication: Procedures, Materials, 
and Applications. Analytical chemistry 89, 7053-7061, 
doi:10.1021/acs.analchem.7b00828 (2017). 
23 Loh, Q. L. & Choong, C. Three-dimensional scaffolds for tissue engineering 
applications: role of porosity and pore size. Tissue engineering. Part B, Reviews 19, 
485-502, doi:10.1089/ten.TEB.2012.0437 (2013). 
24 Martin, I., Wendt, D. & Heberer, M. The role of bioreactors in tissue engineering. 
Trends Biotechnol 22, 80-86, doi:10.1016/j.tibtech.2003.12.001 (2004). 
25 Thevenot, P., Nair, A., Dey, J., Yang, J. & Tang, L. Method to analyze three-
dimensional cell distribution and infiltration in degradable scaffolds. Tissue 
engineering. Part C, Methods 14, 319-331, doi:10.1089/ten.tec.2008.0221 (2008). 
26 Bonewald, L. F. et al. von Kossa staining alone is not sufficient to confirm that 
mineralization in vitro represents bone formation. Calcified tissue international 72, 
537-547, doi:10.1007/s00223-002-1057-y (2003). 
27 McQuillan, D. J., Richardson, M. D. & Bateman, J. F. Matrix deposition by a calcifying 
human osteogenic sarcoma cell line (SAOS-2). Bone 16, 415-426 (1995). 
28 Golub, E. E. & Boesze-Battaglia, K. The role of alkaline phosphatase in 
mineralization. Curr Opin Orthop 18, 444-448 (2007). 
29 Stefkova, K., Prochazkova, J. & Pachernik, J. Alkaline Phosphatase in Stem Cells. 
Stem Cells International 2015 (2015). 
30 Mayr-Wohlfart, U., Fiedler, J., Gunther, K. P., Puhl, W. & Kessler, S. Proliferation and 
differentiation rates of a human osteoblast-like cell line (SaOS-2) in contact with 
different bone substitute materials. J Biomed Mater Res 57, 132-139, 
doi:10.1002/1097-4636(200110)57:1<132::AID-JBM1152>3.0.CO;2-K *pii+ (2001). 
31 Bouleftour, W. et al. The role of the SIBLING, Bone Sialoprotein in skeletal biology - 
Contribution of mouse experimental genetics. Matrix biology : journal of the 
International Society for Matrix Biology 52-54, 60-77, 
doi:10.1016/j.matbio.2015.12.011 (2016). 
 
D
ow
nl
oa
de
d 
by
 T
H
E 
U
N
IV
ER
SI
TY
 O
F 
M
A
N
CH
ES
TE
R 
fro
m
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
3/
08
/1
9.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 17 of 26 
 
 
 
17 
Ti
ss
u
e 
En
gi
n
ee
ri
n
g 
B
io
co
m
p
at
ib
le
 3
D
 p
ri
n
te
d
 t
h
er
m
o
p
la
st
ic
 s
ca
ff
o
ld
s 
fo
r 
o
st
eo
b
la
st
 d
if
fe
re
n
ti
at
io
n
 o
f 
eq
u
in
e 
iP
S 
ce
lls
 (
D
O
I:
 1
0
.1
0
8
9
/t
en
.T
EC
.2
0
1
8
.0
3
4
3
) 
Th
is
 p
ap
er
 h
as
 b
e
e
n
 p
ee
r-
re
vi
e
w
ed
 a
n
d
 a
cc
ep
te
d
 f
o
r 
p
u
b
lic
at
io
n
, b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
go
 c
o
p
ye
d
it
in
g 
an
d
 p
ro
o
f 
co
rr
e
ct
io
n
. T
h
e 
fi
n
al
 p
u
b
lis
h
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
 
32 Graneli, C. et al. Novel markers of osteogenic and adipogenic differentiation of 
human bone marrow stromal cells identified using a quantitative proteomics 
approach. Stem Cell Res 12, 153-165, doi:S1873-5061(13)00135-9 *pii+ 
10.1016/j.scr.2013.09.009 *doi+ (2014). 
33 Huang, W., Yang, S., Shao, J. & Li, Y. P. Signaling and transcriptional regulation in 
osteoblast commitment and differentiation. Front Biosci 12, 3068-3092, doi:2296 
*pii+ (2007). 
34 Jikko, A., Harris, S. E., Chen, D., Mendrick, D. L. & Damsky, C. H. Collagen integrin 
receptors regulate early osteoblast differentiation induced by BMP-2. Journal of 
bone and mineral research : the official journal of the American Society for Bone 
and Mineral Research 14, 1075-1083, doi:10.1359/jbmr.1999.14.7.1075 (1999). 
35 Jundt, G., Berghauser, K. H., Termine, J. D. & Schulz, A. Osteonectin--a 
differentiation marker of bone cells. Cell and tissue research 248, 409-415 (1987). 
36 Köllmer, M., Buhrman, J. S., Zhang, Y. & Gemeinhart, R. A. Markers Are Shared 
Between Adipogenic and Osteogenic Differentiated Mesenchymal Stem Cells. 
Journal of developmental biology and tissue engineering 5, 18-25, 
doi:10.5897/JDBTE2013.0065 (2013). 
37 Rosset, E. M. & Bradshaw, A. D. SPARC/osteonectin in mineralized tissue. Matrix 
biology : journal of the International Society for Matrix Biology 52-54, 78-87, 
doi:10.1016/j.matbio.2016.02.001 (2016). 
38 Mundlos, S., Schwahn, B., Reichert, T. & Zabel, B. Distribution of osteonectin mRNA 
and protein during human embryonic and fetal development. J Histochem 
Cytochem 40, 283-291, doi:10.1177/40.2.1552170 (1992). 
39 Zoch, M. L., Clemens, T. L. & Riddle, R. C. New insights into the biology of 
osteocalcin. Bone 82, 42-49, doi:10.1016/j.bone.2015.05.046 (2016). 
40 Weinreb, M., Shinar, D. & Rodan, G. A. Different pattern of alkaline phosphatase, 
osteopontin, and osteocalcin expression in developing rat bone visualized by in situ 
hybridization. Journal of bone and mineral research : the official journal of the 
American Society for Bone and Mineral Research 5, 831-842, 
doi:10.1002/jbmr.5650050806 (1990). 
D
ow
nl
oa
de
d 
by
 T
H
E 
U
N
IV
ER
SI
TY
 O
F 
M
A
N
CH
ES
TE
R 
fro
m
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
3/
08
/1
9.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 18 of 26 
 
 
 
18 
Ti
ss
u
e 
En
gi
n
ee
ri
n
g 
B
io
co
m
p
at
ib
le
 3
D
 p
ri
n
te
d
 t
h
er
m
o
p
la
st
ic
 s
ca
ff
o
ld
s 
fo
r 
o
st
eo
b
la
st
 d
if
fe
re
n
ti
at
io
n
 o
f 
eq
u
in
e 
iP
S 
ce
lls
 (
D
O
I:
 1
0
.1
0
8
9
/t
en
.T
EC
.2
0
1
8
.0
3
4
3
) 
Th
is
 p
ap
er
 h
as
 b
e
e
n
 p
ee
r-
re
vi
e
w
ed
 a
n
d
 a
cc
ep
te
d
 f
o
r 
p
u
b
lic
at
io
n
, b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
go
 c
o
p
ye
d
it
in
g 
an
d
 p
ro
o
f 
co
rr
e
ct
io
n
. T
h
e 
fi
n
al
 p
u
b
li
sh
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
 
41 Mayr-Wohlfart, U., Fiedler, J., Gunther, K. P., Puhl, W. & Kessler, S. Proliferation and 
differentiation rates of a human osteoblast-like cell line (SaOS-2) in contact with 
different bone substitute materials. J Biomed Mater Res 57, 132-139 (2001). 
42 Ataie, M., Shabani, I. & Seyedjafari, E. Surface mineralized Hybrid Nanofibrous 
Scaffolds Based On Poly(L-lactide) and Alginate Enhances Osteogenic Differentiation 
of Stem Cells. Journal of biomedical materials research. Part A, 
doi:10.1002/jbm.a.36574 (2018). 
43 Liu, Z. et al. The tumourigenicity of iPS cells and their differentiated derivates. J Cell 
Mol Med 17, 782-791, doi:10.1111/jcmm.12062 (2013). 
44 Lepage, S. I. et al. Generation, Characterization, and Multilineage Potency of 
Mesenchymal-Like Progenitors Derived from Equine Induced Pluripotent Stem Cells. 
Stem Cells Dev 25, 80-89, doi:10.1089/scd.2014.0409 (2016). 
45 Ghassemi, T. et al. Current Concepts in Scaffolding for Bone Tissue Engineering. The 
archives of bone and joint surgery 6, 90-99 (2018). 
46 Sheikh, Z. et al. Biodegradable Materials for Bone Repair and Tissue Engineering 
Applications. Materials (Basel, Switzerland) 8, 5744-5794, doi:10.3390/ma8095273 
(2015). 
47 Dorati, R. et al. Biodegradable Scaffolds for Bone Regeneration Combined with 
Drug-Delivery Systems in Osteomyelitis Therapy. Pharmaceuticals (Basel, 
Switzerland) 10, 96, doi:10.3390/ph10040096 (2017). 
48 Shimko, D. A. & Nauman, E. A. Development and characterization of a porous 
poly(methyl methacrylate) scaffold with controllable modulus and permeability. 
Journal of biomedical materials research. Part B, Applied biomaterials 80, 360-369, 
doi:10.1002/jbm.b.30605 (2007). 
49 Evans, G. P., Behiri, J. C., Vaughan, L. C. & Bonfield, W. The response of equine 
cortical bone to loading at strain rates experienced in vivo by the galloping horse. 
Equine Vet J 24, 125-128 (1992). 
  
D
ow
nl
oa
de
d 
by
 T
H
E 
U
N
IV
ER
SI
TY
 O
F 
M
A
N
CH
ES
TE
R 
fro
m
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
3/
08
/1
9.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 19 of 26 
 
 
 
19 
Ti
ss
u
e 
En
gi
n
ee
ri
n
g 
B
io
co
m
p
at
ib
le
 3
D
 p
ri
n
te
d
 t
h
er
m
o
p
la
st
ic
 s
ca
ff
o
ld
s 
fo
r 
o
st
eo
b
la
st
 d
if
fe
re
n
ti
at
io
n
 o
f 
eq
u
in
e 
iP
S 
ce
lls
 (
D
O
I:
 1
0
.1
0
8
9
/t
en
.T
EC
.2
0
1
8
.0
3
4
3
) 
Th
is
 p
ap
er
 h
as
 b
e
e
n
 p
ee
r-
re
vi
e
w
ed
 a
n
d
 a
cc
ep
te
d
 f
o
r 
p
u
b
lic
at
io
n
, b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
go
 c
o
p
ye
d
it
in
g 
an
d
 p
ro
o
f 
co
rr
e
ct
io
n
. T
h
e 
fi
n
al
 p
u
b
lis
h
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
 
Reprint Author 
Dr Deborah Guest, Centre for Preventive Medicine, Animal Health Trust, Lanwades Park, 
Kentford, Newmarket, Suffolk, CB8 7UU, UK  
  
D
ow
nl
oa
de
d 
by
 T
H
E 
U
N
IV
ER
SI
TY
 O
F 
M
A
N
CH
ES
TE
R 
fro
m
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
3/
08
/1
9.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 20 of 26 
 
 
 
20 
Ti
ss
u
e 
En
gi
n
ee
ri
n
g 
B
io
co
m
p
at
ib
le
 3
D
 p
ri
n
te
d
 t
h
er
m
o
p
la
st
ic
 s
ca
ff
o
ld
s 
fo
r 
o
st
eo
b
la
st
 d
if
fe
re
n
ti
at
io
n
 o
f 
eq
u
in
e 
iP
S 
ce
lls
 (
D
O
I:
 1
0
.1
0
8
9
/t
en
.T
EC
.2
0
1
8
.0
3
4
3
) 
Th
is
 p
ap
er
 h
as
 b
e
e
n
 p
ee
r-
re
vi
e
w
ed
 a
n
d
 a
cc
ep
te
d
 f
o
r 
p
u
b
lic
at
io
n
, b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
go
 c
o
p
ye
d
it
in
g 
an
d
 p
ro
o
f 
co
rr
e
ct
io
n
. T
h
e 
fi
n
al
 p
u
b
li
sh
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
 
Table 1 Primer sequences for equine gene transcripts. 
Gene Forward Reverse 
18S CCCAGTGAGAATGCCCTCTA 
 
TGGCTGAGCAAGGTGTTATG 
 
COL1A1 TGCGAAGACACCAAGAACTG 
 
GACTCCTGTGGTTTGGTCGT 
 
SPARC TGGCGAGTTTGAGAAGGTGT 
 
TTTGCAAGGCCCGATGTAGT   
 
SPP1 AGCCCCAGGAAAAATCGCTG 
 
GGCATAAGCAAATCACGGCA 
 
IBSP GGACTGCACACGGAAACAATC 
 
ACAGGCCATTCCCAAAATGC 
 
RUNX2 CCAAGTGGCAAGGTTCAACG 
 
AACTCTTGCCTCGTCCACTC 
 
BGALP GTCTCGGGGTTCCAAGGTTA 
 
AATCTCTGGTAGCTGTGTTGGT 
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Figure legends 
 
Figure 1. The 3D scaffolds can be printed to fit into a standard 24 well tissue culture plate.  
A) Photograph of the scaffold construct showing bulk size. B) Photograph of the scaffold 
demonstrating that it is transparent. Scale bar = 5 mm. C) Micrograph showing a magnified 
view of the scaffold to demonstrate the scaffold pores. Scale bar = 1200 µm. D) 
Photograph of the scaffold in culture conditions. Scale bar = 5 mm. E) A conceptual 
schematic of the scaffolds with the filament shown in yellow, the mesh layer in blue and 
cells represented in grey.  
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Figure 2. 3T3 mouse fibroblasts and human Soas-2 cells can attach and proliferate to the 
3D scaffolds. A) SEM of the scaffold in the absence (i) and presence (ii and iii) of 3T3 cells 
after 9 days of culture. The red arrow highlights attached cells. B) GFP labelled Saos-2 cells 
grow better on enclosed scaffolds than open scaffolds. Soas-2 cells adhere to the both 
open (i) and enclosed (ii) scaffolds but large numbers of cells pass through the open 
scaffolds onto the base of the tissue culture plate in the open (iii) but not the enclosed (iv) 
scaffolds.  Scale bar in i and ii = 400 µm. Scale bar in iii and iv = 30 µm. 
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Figure 3. GFP labelled iPSCs seeded as colonies and differentiated for 21 days on the 3D 
scaffold. iPSC colonies (indicated by *) adhere to the scaffold and cells migrate out along 
the scaffold fibres (A - D). However, after 21 days of culture, iPS-derived cells are fewer in 
number and less evenly distributed than Saos-2 cells (E). Four images of the iPSCs are 
provided to demonstrate the heterogeneity in their distribution. A single representative 
image of a scaffold seeded with Saos-2 is shown as these cells were homogenously 
distributed. Scale bar = 400 µm. 
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Figure 4. iPSCs differentiated on the 3D scaffold produce a mineralised matrix. A) von 
Kossa staining for calcium on constructs seeded with i) iPSCs, ii) no cells (blank construct) 
or iii) Saos-2 cells. Positive staining is shown in black/brown. B) Alizarin red S staining for 
calcium with positive staining shown in red. Scale bar in A and B = 1200 µm. C) 
Hydroxyapatite staining with deposits fluorescing green.  iPSC images are  representative 
of four replicates using four independent clonal iPSCs derived from two different horses. 
Scale bar in C = 400 µm. 
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Figure 5. iPSCs differentiated on the 3D scaffold have increasing alkaline phosphatase 
activity (ALP) with time. Error bars represent the standard error of the mean from a total 
of six clonal lines of iPSCs derived from three different horses. ALP from on replicate of 
Saos-2 cells differentiated on the 3D scaffold was measured as a positive control. 
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Figure 6. iPSCs differentiated on the 3D scaffolds for 21 days express osteoblast associated 
genes and proteins. A) Relative gene expression (on a log10 scale) of osteoblast associated 
genes. N.D. = expression not detected. B) Differentiated iPSCs express detectable levels of 
all osteoblast proteins except for IBSP. Scale bars = 400 µm. 
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